A new third generation bisphosphonate, risedronate (Actonel), is now available, joining two existing members of this therapeutic class. This article describes the evidence supporting the use of risedronate in osteoporosis and Paget’s disease.
What do we know about risedronate?
Risedronate, a third-generation bisphosphonate, has potent antiresorptive activity in bone and is therefore of interest in treating metabolic bone disorders. Its efficacy has been evaluated extensively in osteoporosis (postmenopausal and corticosteroid-induced) and Paget’s disease.